Breast Cancer: Causes, Symptoms, Treatment

Breast cancer is a malignant disease originating in the breast tissue, usually developing within the milk-producing ducts or the lobules that supply them. It represents a massive global health burden and stands as the most frequently diagnosed cancer worldwide.

In the UK, breast cancer is the single most common cancer overall, accounting for roughly 15% of all new cancer cases. Every year brings over 56,800 new diagnoses and approximately 11,300 related deaths, making it the second biggest cancer killer in British women.

In 2026, breast oncology focuses on expanding risk-stratified digital mammography screening, advanced genomic profiling of early-stage tumours to avoid unnecessary chemotherapy, and utilising targeted antibody-drug conjugates (ADCs) to arrest metastatic progression.

1. Incidence and Statistics

The epidemiology of breast cancer highlights its profound impact across specific demographics:

• Gender Balance: While predominantly affecting women, it is not exclusively female; roughly 370 men are diagnosed with breast cancer each year in the UK.

• Age Distribution: Incidence rises sharply with age. More than 80% of cases occur in women aged 50 and over, with the highest rates concentrated in the 50–69 age demographic, aligned with the national screening window.

• Socioeconomic Impact: While overall incidence can be higher in more affluent areas (often linked to reproductive factors), mortality and late-stage presentation rates remain disproportionately high in socioeconomically deprived communities.

2. Types and Pathological Classifications

Clinicians categorise breast cancers based on cellular origin and hormone receptor status, which fundamentally dictates treatment pathways:

• Invasive Ductal and Lobular Carcinoma: Invasive Ductal Carcinoma (IDC) is the most common form, accounting for roughly 80% of cases. Invasive Lobular Carcinoma (ILC) accounts for about 10–15% and can be harder to detect on standard imaging.

• Hormone Receptor Status (ER/PR+): Tumours are tested for Estrogen (ER) and Progesterone (PR) receptors. Receptor-positive cancers grow in response to these hormones and are highly treatable with endocrine therapies.

• HER2 Status and Triple-Negative: Tumours are evaluated for HER2 protein overexpression. Cancers lacking ER, PR, and HER2 express structural vulnerability and are termed Triple-Negative Breast Cancer (TNBC), requiring aggressive systemic strategies.

3. Causes and Risk Factors (Modifiable vs. Genetic)

The risk profile involves a complex interplay between lifestyle choices and deeply impactful genetic alterations.

4. Typical Symptoms and Red Flag Signs

In its early stages, breast cancer may cause no pain or visible changes, making routine NHS breast screening mammograms vital for women aged 50–70. As a tumour grows, clear red flag signs emerge:

• A New Lump or Thickening: A distinct, often painless, hard lump in the breast tissue or axilla (underarm) that feels different from the surrounding area.

• Skin Alterations: Dimpling, puckering, or redness of the breast skin, sometimes resembling the pitted texture of an orange peel (peau d’orange).

• Nipple Changes: A newly inverted or turned-in nipple, or a sudden change in its shape or position.

5. Atypical and Systemic Signs

Some presentations deviate from a standard localized lump, appearing as inflammatory changes or systemic signs:

• Nipple Discharge: Spontaneous discharge from a single nipple, particularly if it is blood-stained or clear, rather than milky.

• Inflammatory Changes: Rapidly progressive swelling, warmth, and redness across the breast without an underlying infection, characteristic of aggressive inflammatory breast cancer.

• Paget’s Disease of the Nipple: An isolated, persistent eczema-like rash, crusting, or itchiness affecting the nipple and surrounding areola.

6. Diagnosis and Screening Protocols

When a breast abnormality is flagged by screening or a physical symptom, a swift “triple assessment” protocol is initiated:

• Clinical Examination: A thorough physical inspection and palpation of both breasts and regional lymph node basins by a specialist clinician.

• Diagnostic Imaging: Digital mammography (breast X-ray) combined with targeted ultrasound imaging. For younger patients or complex cases, a breast MRI is heavily utilized.

• Core Needle Biopsy & Genomic Profiling: Extracting tissue samples to confirm malignancy. In 2026, standard early-stage management dictates using genomic assays (like Oncotype DX) to predict whether chemotherapy will offer any survival benefit.

7. Staging and Classification

Staging guides the clinical multidisciplinary team in deciding between curative regional treatment or systemic control:

• Stage 1 & 2: The cancer is relatively small and localized to the breast tissue, or has spread minimally to a small number of mobile axillary lymph nodes.

• Stage 3 (Locally Advanced): The tumour has grown larger, invaded the chest wall or overlying skin, or spread extensively to fixed matted lymph nodes.

• Stage 4 (Metastatic): Malignant cells have migrated via the vascular or lymphatic channels to colonise distant organ systems—most frequently the bones, liver, lungs, or brain.

8. Treatment (2026 Standards)

Modern therapeutic protocols provide highly personalized, multi-modal treatment schedules determined by molecular subtype:

• Surgical Management: Breast-conserving surgery (lumpectomy) followed by radiotherapy is favored for localized disease, providing equivalent survival rates to a full mastectomy while preserving tissue.

• Targeted Antibody-Drug Conjugates (ADCs): For HER2-positive or HER2-low advanced disease, 2026 standards rely on smart therapies like Trastuzumab Deruxtecan, delivering cytotoxic chemotherapy directly to targeted cancer cells.

• Endocrine (Hormone) Therapy: For ER-positive tumours, long-term daily medications such as Tamoxifen or Aromatase Inhibitors (e.g., Anastrozole) are prescribed for 5–10 years post-surgery to suppress estrogen pathways.

• Neoadjuvant Systemic Therapy: Administering tailored chemotherapy combined with immunotherapies (like Pembrolizumab) prior to surgery for Triple-Negative disease to shrink tumours and clear nodal involvement early.

9. Complications and Outlook

Continuous therapeutic innovation has substantially optimized long-term survival, though significant clinical hurdles remain:

• Survival Rates: When diagnosed at Stage 1, the 5-year survival rate exceeds 95%. However, late presentations lower the overall 5-year survival rate across all stages to roughly 85%, dropping to 25% for Stage 4.

• Treatment Side Effects: Axillary lymph node clearance can trigger chronic lymphoedema (painful fluid swelling of the arm), while systemic hormone therapies can induce premature menopause and accelerated bone density loss.

• Organ-Specific Metastasis: Advanced progression can cause debilitating skeletal pain, fractures, or neurological complications if the disease crosses into the central nervous system.

10. When to See a Doctor

If you notice a new lump in your breast or armpit, skin dimpling, nipple inversion, or unusual discharge, contact your GP surgery promptly for a priority referral to a local one-stop breast clinic.

Top Tip: Never skip your NHS mammogram appointment just because you feel completely well or your breasts look unchanged. Mammograms routinely catch microscopic calcifications and structural distortions years before they can be felt as a physical lump. Knowing your normal breast structure through regular self-checks remains a simple habit that can save your life.

Summary

Breast cancer remains a highly prevalent health condition, yet the combination of early detection networks and biomarker-driven therapeutics makes it one of the most manageable malignancies when intercepted early. Reducing modifiable risk factors like alcohol intake and keeping an active lifestyle form the foundation of public health preventative measures.

For patients navigating a diagnosis in 2026, the transition toward tailored de-escalation of treatment—using genomic testing to safely bypass chemotherapy alongside advanced, targeted antibody-drug conjugates—continues to maximise survival outcomes while preserving long-term quality of life.